Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Marking hypoxic cells for complement and cytotoxic T lymphocyte-mediated lysis: using pimonidazole.

Literature DB >> 8763883

Marking hypoxic cells for complement and cytotoxic T lymphocyte-mediated lysis: using pimonidazole.

Abstract

Artificial antigens are created when 2-nitroimidazoles bind to hypoxic cells. These antigens have been used in the immunodetection of tumour hypoxia but they might also serve to stimulate immune lysis of hypoxic tumour cells by complement- and cell-mediated processes. In order to test this hypothesis, lymphocytes isolated from the spleens of C3H/HeN mice that had been immunised with pimonidazole-labelled 3152-PRO cells were subcultured and tested for their ability to lyse chromium-51 loaded, pimonidazole-labelled 3152-PRO cells in an in vitro assay. In a parallel study, commercially available, rabbit complement was tested for its ability to lyse pimonidazole-labelled V79-4 cells in the presence of monoclonal antibodies which recognise protein adducts of reductively activated pimonidazole. Complement-mediated cell lysis was measured by means of an MTT assay. Complement-mediated and cell-mediated lysis was observed at pimonidazole concentrations which, in themselves, do not produce cell killing.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1996 PMID： 8763883 PMCID： PMC2150013

Source DB: PubMed Journal: Br J Cancer Suppl ISSN： 0306-9443

14 in total

Review 1. Potential immunogenicity of oncogene and tumor suppressor gene products.

Authors: C J Melief; W M Kast
Journal: Curr Opin Immunol Date: 1993-10 Impact factor: 7.486

2. Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules.

Authors: J A Raleigh; C J Koch
Journal: Biochem Pharmacol Date: 1990-12-01 Impact factor: 5.858

3. Biological characterization of a chimeric mouse-human IgM antibody directed against the 17-1A antigen.

Authors: W E Fogler; L K Sun; M R Klinger; J Ghrayeb; P E Daddona
Journal: Cancer Immunol Immunother Date: 1989 Impact factor: 6.968

4. Production of interleukin 2 and interleukin 4 by immune CD4-CD8+ and their role in the generation of antigen-specific cytotoxic T cells.

Authors: B Horvat; J A Loukides; L Anandan; E Brewer; P M Flood
Journal: Eur J Immunol Date: 1991-08 Impact factor: 5.532

5. Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: comparison with experimental data.

Authors: L T Baxter; F Yuan; R K Jain
Journal: Cancer Res Date: 1992-10-15 Impact factor: 12.701

6. Contrasuppression and tumor rejection.

Authors: P M Flood; A Friedman; B Horvat; P Reuter; A Rodriquez; W Ptak
Journal: Immunol Lett Date: 1987-12 Impact factor: 3.685

7. Distribution of the hypoxia marker CCI-103F in canine tumors.

Authors: J M Cline; D E Thrall; G L Rosner; J A Raleigh
Journal: Int J Radiat Oncol Biol Phys Date: 1994-03-01 Impact factor: 7.038

8. ELISA quantification of CCI-103F binding in canine tumors prior to and during irradiation.

Authors: D E Thrall; M C McEntee; J M Cline; J A Raleigh
Journal: Int J Radiat Oncol Biol Phys Date: 1994-02-01 Impact factor: 7.038

9. Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours.

Authors: J M Cline; D E Thrall; R L Page; A J Franko; J A Raleigh
Journal: Br J Cancer Date: 1990-12 Impact factor: 7.640

10. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver.

Authors: G E Arteel; R G Thurman; J M Yates; J A Raleigh
Journal: Br J Cancer Date: 1995-10 Impact factor: 7.640

4 in total

1. Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments.

Authors: Georg Fluegen; Alvaro Avivar-Valderas; Yarong Wang; Michael R Padgen; James K Williams; Ana Rita Nobre; Veronica Calvo; Julie F Cheung; Jose Javier Bravo-Cordero; David Entenberg; James Castracane; Vladislav Verkhusha; Patricia J Keely; John Condeelis; Julio A Aguirre-Ghiso
Journal: Nat Cell Biol Date: 2017-01-23 Impact factor: 28.824

Marking hypoxic cells for complement and cytotoxic T lymphocyte-mediated lysis: using pimonidazole.

Review 1. Potential immunogenicity of oncogene and tumor suppressor gene products.

2. Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules.

3. Biological characterization of a chimeric mouse-human IgM antibody directed against the 17-1A antigen.

4. Production of interleukin 2 and interleukin 4 by immune CD4-CD8+ and their role in the generation of antigen-specific cytotoxic T cells.

5. Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: comparison with experimental data.

6. Contrasuppression and tumor rejection.

7. Distribution of the hypoxia marker CCI-103F in canine tumors.

8. ELISA quantification of CCI-103F binding in canine tumors prior to and during irradiation.

9. Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours.

10. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver.

1. Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments.

2. Hypoxia in renal disease with proteinuria and/or glomerular hypertension.

3. Targeting Artificial Tumor Stromal Targets for Molecular Imaging of Tumor Vascular Hypoxia.

Review 4. The tumour microenvironment links complement system dysregulation and hypoxic signalling.

Review 1. Potential immunogenicity of oncogene and tumor suppressor gene products.

Review 4. The tumour microenvironment links complement system dysregulation and hypoxic signalling﻿.

Review 4. The tumour microenvironment links complement system dysregulation and hypoxic signalling.